SUMM.L Share News (SUMM)

Summit Therapeutics first-quarter pre-tax loss widens

Drug discovery and development company Summit Therapeutics posted a 52.6% widening in its first-quarter pre-tax loss, pointing to the cost of listing on the NASDAQ and higher research and development costs. The pre-tax losses came in at $5.8m compared with $3.8m in the same period last year. In the

Summit Therapeutics First Quarter Loss Widens On Higher Costs

BUZZ-Sarepta news lifts other muscular distrophy stocks

** Companies developing muscular distrophy treatments, PTC Therapeutics and Summit Therapeutics had their shares boosted on Wednesday by positive regulatory news from a third firm in the same space, Sarepta Therapeutics ** PTC shares rose as much as 7.2 percent during the session and were

Port Erin Biopharma Swings To First Half Loss As Gains Do Not Recur

BUZZ-Summit Therapeutics Plc: Shares rise in debut

** Biopharmaceutical company's U.S.-listed shares up 2.7 pct at $10.20 ** Stock rises as much as 4.5 pct to $10.35, valuing company at $120.8 mln ** Offering of 3.45 American depository shares priced at $9.90 each ** IPO raised about $34.15 mln

UK MORNING BRIEFING: Centrica Shares Fall 7.7% On Loss, Dividend Cut

UK AGM, EGM Calendar - Week Ahead

UK AGM, EGM Calendar - Week Ahead

UK AGM, EGM Calendar - Week Ahead

UK AGM, EGM Calendar - Week Ahead

UK AGM, EGM Calendar - Week Ahead

UK AGM, EGM Calendar - Week Ahead

UK AGM, EGM Calendar - Week Ahead

UK AGM, EGM Calendar - Week Ahead

UK AGM, EGM Calendar - Week Ahead